FDA Issues Nationwide Recall of Thyroid Drug

The Food and Drug Administration has issued a nationwide recall of levothyroxine sodium tablets made by Major Pharmaceuticals, citing concerns that certain lots are subpotent and may not deliver the intended dose.

Details of the recall

The recall, classified as a Class II action, applies to specific lot numbers and expiration dates listed by the agency. Affected tablets were packaged in 10‑count blister packs, either sold individually or grouped into cartons of ten blister packs. The notice identifies the following strengths and lot information:

• 25 mcg, 100‑tablet carton – Lot N02212, Exp 07/2026
• 50 mcg, 100‑tablet carton – Lot N02200, Exp 10/2026
• 75 mcg, 100‑tablet carton – Lots N02172, N02296, N02288, Exp 07/2026, 12/2026
• 88 mcg, 100‑tablet carton – Lot N02310, Exp 01/2027
• 112 mcg, 100‑tablet carton – Lot N02203, Exp 09/2026
• 125 mcg, 100‑tablet carton – Lot N02266, Exp 11/2026
• 150 mcg, 100‑tablet carton – Lot N02167, Exp 07/2026
• 25 mcg, 10‑tablet blister pack – Bag lots N02212A, N02212B; Blister lot N02212, Exp 07/2026
• 50 mcg, 10‑tablet blister pack – Bag lots N02200A, N02200B; Blister lot N02200, Exp 10/2026
• 75 mcg, 10‑tablet blister pack – Bag lots N02172A, N02172B, N02288A, N02288B; Blister lots N02172, N02288, Exp 07/2026, 12/2026
• 125 mcg, 10‑tablet blister pack – Bag lots N02266A, N02266B; Blister lot N02266, Exp 11/2026
• 150 mcg, 10‑tablet blister pack – Bag lots N02167A, N02167B; Blister lot N02167, Exp 07/2026

What patients should do

Anyone who uses levothyroxine for hypothyroidism, goiter or related conditions should check their medicine cabinet against the lot numbers above.

If a match is found, the agency advises patients not to stop taking the drug without guidance, as abrupt discontinuation can cause symptoms such as fatigue, weight gain, or heart rhythm changes.

Related: Hand Arthritis Causes and Treatment Options

Instead, patients should contact their pharmacist or prescribing physician. Health professionals can confirm whether a specific batch is affected and may provide an alternative supply, adjust the dosage, or arrange a temporary replacement.

The subpotent issue appears limited to the identified lots, according to the agency’s findings.

For patients, the practical impact is largely a matter of verification and communication. The notice does not suggest that the tablets are dangerous; rather, they may deliver less hormone than expected, potentially leading to under‑treatment if unnoticed.

This nuance matters because many individuals rely on consistent dosing to maintain metabolic balance.

Related: Rugby Training Tips from Junior Nsemba

Medication recalls, though unsettling, are part of a safety net designed to protect public health.

The company has not yet released a statement regarding the cause of the subpotency, but the recall highlights the importance of rigorous quality control in drug manufacturing.

The classification of the recall as Class II indicates that while the risk is not life‑threatening, it is still significant enough to warrant prompt action.